Home
>
National Drug Code (NDC)
>
Rapamune
Rapamune - 0008-1040-05 - (SIROLIMUS)
Drug Information of Rapamune
| Product NDC: | 0008-1040 |
| Proprietary Name: | Rapamune |
| Non Proprietary Name: | SIROLIMUS |
| Active Ingredient(s): | .5 mg/1 & nbsp; SIROLIMUS |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, SUGAR COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Rapamune
| Product NDC: | 0008-1040 |
| Labeler Name: | Wyeth Pharmaceuticals Company, a subsidiary of Pfizer Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021110 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20100301 |
Package Information of Rapamune
| Package NDC: | 0008-1040-05 |
| Package Description: | 100 TABLET, SUGAR COATED in 1 BOTTLE (0008-1040-05) |
NDC Information of Rapamune
| NDC Code | 0008-1040-05 |
| Proprietary Name | Rapamune |
| Package Description | 100 TABLET, SUGAR COATED in 1 BOTTLE (0008-1040-05) |
| Product NDC | 0008-1040 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | SIROLIMUS |
| Dosage Form Name | TABLET, SUGAR COATED |
| Route Name | ORAL |
| Start Marketing Date | 20100301 |
| Marketing Category Name | NDA |
| Labeler Name | Wyeth Pharmaceuticals Company, a subsidiary of Pfizer Inc. |
| Substance Name | SIROLIMUS |
| Strength Number | .5 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Decreased Immunologic Activity [PE],mTOR Inhibitor Immunosuppressant [EPC],mTOR Inhibitors [MoA] |
